Industry-sponsored sessions

Thursday 05 October 2017

11:45 to 12:45

The Future is Now: Changes in Patient Care and Outcomes in Locally Advanced and Metastatic Urothelial Cancer

Chair: Robert Jones
Speakers: Joaquim Bellmunt,  Robert Jones, Shahrokh F. Shariat
11:45-11:49 - Welcome and Opening remarks
11:49-12:01 - Role of PD-1 Pathway Inhibition in mUC - J. Bellmunt, US
12:01-12:13 - Quality of Life (QoL) considerations for mUC patients - R. Jones, UK
12:13-12:25 - Clinical aspects of immunotherapy in urothelial carcinoma - S. Shariat, Austria
12:25-12:45 - Panel Discussion / Q&A / Closing remarks

Friday 06 October 2017

10:05 to 10:35

Checkpoint Inhibitors: Important Practical Information

Chair: Maria De Santis
Speaker: Ignacio Durán

11:05 to 11:35

Emerging Research on the Role of Checkpoint Inhibitors in Bladder Cancer

Chair: Maria De Santis
Speaker: John Wagstaff